<DOC>
	<DOCNO>NCT01742052</DOCNO>
	<brief_summary>The primary objective study : - To evaluate effect three oral dos MT-1303 compare placebo give period 24 week subject relapsing-remitting multiple sclerosis ( RRMS ) MRI parameter - To evaluate safety tolerability three oral dos MT-1303 compare placebo give period 24 week subject RRMS .</brief_summary>
	<brief_title>Dose-finding Study MT-1303</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>RRMS define revise McDonald criterion Evidence recent MS activity define either : least one document relapse previous 12 month , OR positive gadolinium ( Gd ) enhance MRI scan within 3 month prior screen , OR least two documented relapse previous 24 month positive Gdenhanced MRI scan within previous 12 month Expanded Disability Status Score ( EDSS ) score ≥0.0 ≤5.5 point . Primary progressive , secondary progressive progressive relapse MS screen Disease duration &gt; 15 year combine EDSS score ≤2.0 Relapse MS Screening Period History know presence neurological disorder likely render subject unsuitable study History list predefined cardiovascular disease History know presence significant central nervous system , infectious , metabolic , oncological , ophthalmological respiratory system disease illness likely render subject unsuitable study Previous exposure sphingosine 1phosphate receptor modulator Receipt live vaccine systemic corticosteroid use within 28 day prior randomisation Previous treatment betainterferons glatiramer acetate within 14 day prior randomisation Previous treatment intravenous immunoglobulin , plasmapheresis , certain immunosuppressant , lymphocytedepleting therapy , total body irradiation bone marrow transplantation Need , likely need , treatment Class I III antiarrhythmic drug heartratelowering betablockers calciumchannel blocker , drug reduce heart rate Evidence significant anaemia , thrombocytopenia , leucopoenia lymphocytopenia , renal hepatic impairment Clinically significant electrocardiogram ( ECG ) finding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>relapsing-remitting multiple sclerosis</keyword>
	<keyword>RRMS</keyword>
</DOC>